Original Article

Bone Mineral Density, Osteoporosis Prevalence and Influential Factors in Osteogenesis in Patients with Beta Thalassemia Major: A Cross-Sectional Study

Abstract

Background: Osteoporosis and osteopenia considered as severe problems in Beta thalassemia major (BTM) that can lead to bone fractures. We aimed to investigate bone mineral density status and the laboratory parameters related to bone metabolism in BTM patients and compare the statically differences between the mentioned parameters in the patients with or without bone fractures.
Methods: The results of laboratory parameters including; Hemoglobin (Hb), Calcium (Ca), Vitamin D (Vit D), Phosphorus (P), Magnesium (Mg), Alkaline Phosphatase (ALP), Ferritin (FER), Serum Iron (SFe), Thyroid Stimulating Hormone (TSH), T3, T4 and Parathyroid Hormone (PTH), and BMD (by using Dual-Energy X-ray Absorptiometry (DEXA) method) were investigated in 143 BTM patients from thalassemia center of Dezful University of Medical Sciences in 2023.
Results: Seventy-two women and 71 men with confirmed BTM diagnosis with age range (32.4 ± 9.7) were entered in the study. Laboratory parameters including TSH, T3, T4, ALP, FER 247) and SFe showed a significant difference between fracture and non-fracture groups respectively (P≤0.05). In this study, Z-Score between -1.1 and -2.4 was considered osteopenia, and below -2.5 was osteoporosis. Among the studied patients 36.6%, 39.1% and 24.2% had normal bone density, osteopenia and had osteoporosis respectively.
Conclusion: Osteopenia and osteoporosis had a high frequency among the studied patients that can prone them to bone fractures. Continuous examinations of laboratory tests, especially T3, T4, TSH, FER, SFE, can be helpful for faster diagnosis and therapeutic interventions to prevent the occurrence of osteopenia and pathological fractures.

1. Riza M, Mulatsih S, Triasih R (2019). Factors associated with insulin-like growth factor-1 in children with thalassemia major. Paediatrica Indonesiana, 59(2):72-8.
2. Li C-K (2017). New trend in the epidemiology of thalassaemia. Best Pract Res Clin Obstet Gynaecol, 39:16-26.
3. Weatherall DJ, Clegg JB (2001). The thalassaemia syndromes. John Wiley & Sons.
4. Taher AT, Musallam KM, Inati A (2009). Iron overload: consequences, assessment, and monitoring. Hemoglobin, 33 Suppl 1:S46-57.
5. Calleja E, Shen J, Lesser M, et al. (1998). Survival and morbidity in transfusion‐dependent thalassemic patients on subcutaneous desferrioxamine chelation: Nearly two decades of experience. Annals of the New York Academy of Sciences, 850(1):469-70.
6. Vogiatzi M, Macklin E, Fung E, et al. (2006). Prevalence of fractures among the Thalassemia syndromes in North America. Bone, 38(4):571-5.
7. Haidar R, Musallam KM, Taher AT (2011). Bone disease and skeletal complications in patients with β thalassemia major. Bone, 48(3):425-32.
8. Balogh E, Paragh G, Jeney V (2018). Influence of iron on bone homeostasis. Pharmaceuticals (Basel), 11(4):107.
9. Wong P, Fuller PJ, Gillespie MT, Milat F (2016). Bone disease in thalassemia: a molecular and clinical overview. Endocr Rev, 37(4):320-46.
10. Vogiatzi MG, Macklin EA, Fung EB, et al. (2009). Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res, 24(3):543-57.
11. Wonke B (1998). Annotation: Bone disease in thalassemia major. Br J Haematol, 103:897-901.
12. Ferrari SL, Abrahamsen B, Napoli N, et al. (2018). Diagnosis and management of bone fragility in diabetes: an emerging challenge. Osteoporos Int, 29(12):2585-2596.
13. Almeida M, Laurent MR, Dubois V, et al. (2017). Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev, 97(1):135-87.
14. Gökbulak F (2003). Effect of American bison (Bison bison L.) on the recovery and germinability of seeds of range forage species. Grass and Forage Science, 57(4):395-400.
15. Wonke B (2001). Clinical management of beta-thalassemia major. Semin Hematol, 38(4):350-9.
16. Vogiatzi MG, Autio KA, Schneider R, Giardina PJ (2004). Low bone mass in prepubertal children with thalassemia major: insights into the pathogenesis of low bone mass in thalassemia. J Pediatr Endocrinol Metab, 17(10):1415-22.
17. Bielinski B, Darbyshire P, Mathers L, et al. (2001). Bone density in the Asian thalassaemic population: a cross‐sectional review. Acta Paediatr, 90(11):1262-6.
18. Yazigi A, Maalouf G, Inati-Khoriati A, et al. (2002). Bone mineral density in beta-thalassemic Lebanese children. J Musculoskelet Neuronal Interact, 2(5):463-8.
19. Karimi M, Ghiam AF, Hashemi A, et al. (2007). Bone mineral density in beta-thalassemia major and intermedia. Indian Pediatr, 44(1):29-32.
20. Vogiatzi MG, Autio KA, Mait JE, et al. (2005). Low bone mineral density in adolescents with β‐thalassemia. Ann N Y Acad Sci, 1054:462-6.
21. Saffari F, Abolfazl M (2008). Bone mineral density in patients with Beta-Thalassemia Major in Qazvin. Journal of Isfahan Medical School, 26(89):175.
22. Landau H, Matoth I, Landau‐Cordova Z, et al. (1993). Cross‐sectional and longitudinal study of the pituitary‐thyroid axis in patients with thalassaemia major. Clin Endocrinol (Oxf), 38(1):55-61.
23. Tsakalidis C, Dokos C, Tragiannidis A, et al. (2010). Gestational age, body weight and bone metabolism markers in premature infants: a single institution experience of Northern Greece. Acta Paediatrica, 99:99.
24. Xia D, Wu J, Xing M, et al. (2019). Iron overload threatens the growth of osteoblast cells via inhibiting the PI3K/AKT/FOXO3a/DUSP14 signaling pathway. J Cell Physiol, 234(9):15668-77.
25. De Sanctis V, Soliman AT, Elsefdy H, et al. (2018). Bone disease in β thalassemia patients: past, present and future perspectives. Metabolism, 80:66-79.
26. Zhang J, Zhao H, Yao G, et al. (2021). Therapeutic potential of iron chelators on osteoporosis and their cellular mechanisms. Biomed Pharmacother, 137:111380.
27. Mylona M, Leotsinides M, Alexandrides T, et al. (2005). Comparison of DXA, QCT and trabecular structure in β‐thalassaemia. Eur J Haematol, 74(5):430-7.
Files
IssueVol 53 No 8 (2024) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v53i8.16294
Keywords
Bone mineral density Osteoporosis Osteopenia Dual-energy x-ray absorptiometry method Beta thalassemia major
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Behzadifard S, Arianezhad A, Nazarinia D, Behmanesh R, Sinaei H, Alinezhad Dezfuli D, Behzadifard M. Bone Mineral Density, Osteoporosis Prevalence and Influential Factors in Osteogenesis in Patients with Beta Thalassemia Major: A Cross-Sectional Study. Iran J Public Health. 2024;53(8):1883-1889.